Marco Moschini

MD PhD FEBU, Urologist, Milano, Italy. @EAUYAUrology Urothelial Carcinoma Group

[Marco Moschini @UroMoschini]

@UroDocAsh @ParamMariappan @LAUrology_NL @achoud72 @MRoupret @joanfundi @LauraBukavinaMD @jteoh_hk @paolo_gontero @BenjaminPradere Missing you, will follow from Milano!

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

New IBCG consensus:
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
(IBCG)

Full text: https://t.co/2ziB2Z24ES

@shilpaonc @AndreaNecchi @UrogerliMD @PGrivasMDPhD @FaltasLab @pjhensley11 @siadaneshmand @niyatilobo @mouwlab @karima_oualla @UroMoschini @BogdanaSchmidt @AStenzl @JoshMeeks @DrRosenbergMSK #OncSurgery

[SIU-Urology @SIU_urology]

🔬✨ Discover the surgical innovations reshaping bladder cancer care on a new Global Perspectives webinar on SIU Academy!
Join top global experts for this informative session on cutting-edge resection techniques, robotic & open radical cystectomy, and real-world strategies to improve outcomes in MIBC.
Watch open access on SIU Academy: https://t.co/aNiGktvYST

@fkorkes @jteoh_hk @UroMoschini @SimonemorraMD

[Prof Ananya💙 @achoud72.bsky.social @achoud72]

What a lovely memento of the #BLADDR25 family. Looking forward to #BLADDR26 in #Amsterdam - come & join us - Dec 2-5 2026! @mirrorsmed @issecam #PROSCA25 #RENALC25

[ecancer @ecancer]

Join us for an interactive seminar on 'Shaping the future: advancing HR-NMIBC management beyond BCG' live from #EMUC25. Register for free here 👉 https://t.co/zWMER9HpQW #bladder #urology #Oncology
@LAUrology_NL @UroMoschini @evanguelosx

[Roberto Contieri @RobertoContieri]

Fantastic #bladdercancer session at #EMUC2025 with a brilliant discussion and a truly stellar panel. So much is chanhing with new treatments, and urologists need to be ready for what’s coming next.
@Uroweb

[Félix Guerrero-Ramos @DrFelixGuerrero]

🤩Happy to be part of this timely collaborative multicenter review
🧪The role of ICIs in #NMIBC
📰Just published in @Cancers_MDPI @MDPIOpenAccess
👓Read it: https://t.co/cHzF91traK
✍️@evanguelosx @BenjaminPradere @UroMoschini among others

[Julian Chavarriaga @chavarriagaj]

📢 New SOC for MIBC
#ESMO25 Dr. Christof Vulsteke presents KEYNOTE-905:
🚫 No cisplatin? No problem. EV+pembro delivers.
👥 n=344 cis-ineligible MIBC (80% renal impairment, 15% ECOG 2)
🔹 EFS HR 0.40 | OS HR 0.50
🔹 pCR: 57.1% vs 8.6% (ITT, non-op = non-responders)
🔹 No ↑ surgical complications
✅ 1st phase 3 trial showing OS benefit in this population| Unprecedented pCR↑
@urotoday @myESMO

[Laura Bukavina @LauraBukavinaMD]

In anticipation of #esmo2025 please find a perfect summary of #bladdercancer trials made by our @UroOnc fellow superstar @hjwang26 .. looking forward to 📊🧑‍💻 ALBAN, POTOMAC @IBCG_BladderCA @CleClinicUro ..

[European School of Urology (EAU ESU) @UrowebESU]

Explore the current definitions, treatment paradigms, & clinical dilemmas of NMIBC in this new #UROwebinar! The experts will address optimal risk stratification, tx duration, & future therapeutic directions.

Register here 👇
https://t.co/X5o7CVGuhW

@LAUrology_NL @UroMoschini

[MolinetteUrology @UroMolinette]

The Urothelial Cancer Update 2025 is officially underway. Esteemed experts are on stage sharing the latest advancements in diagnosis and treatment. ​What has been the most impactful session for you so far? Let us know in the comments! 👇
@cittasalute_to @unito @UroMolinette

[Marco Moschini @UroMoschini]

@steffiyuen @drkemalsarica Congrats!!

[Petros Grivas @PGrivasMDPhD]

Agree with @shilpaonc amazing growth of @IBCG_BladderCA with global mission bringing experts together to develop guidelines based on evidence & consensus! @UrogerliMD @UroMoschini @spsutkaMD @MaxKates @siadaneshmand @shilpaonc @SpiessPhilippe @WesKassouf @AndreaNecchi @UroDocAsh

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Thrilled to welcome over 100 global experts and patient advocates to Houston for #IBCG25!

Together we’ll focus on two crucial goals: integrating bladder cancer biomarkers into clinical practice, and developing tools to better monitor and address local bladder toxicity - guided by the patient voice.

Both topics reflect our @IBCG_BladderCA mission: to create real-world solutions that improve outcomes and provide practical tools for patients worldwide; through collaboration, collaboration and ... more collaboration!

@shilpaonc @UrogerliMD @pjhensley11 @BladderCancerUS @WorldBladderCan @AndreaNecchi @PGrivasMDPhD @siadaneshmand @bbmdmsk @MaxKates @VigneshPackiam @LauraBukavinaMD @drtanws @niyatilobo @MarekBabjuk @joanfundi @RobertoContieri @mouwlab @OAlhalabiMD @urotoday @WesKassouf @SimaPorten @UroMoschini @LAUrology_NL @AStenzl @Agarwal_CaB @marigfern @spsutkaMD @jteoh_hk @Heer_Lab @SpiessPhilippe @SWilliams_MD @achoud72 @paolo_gontero @JanetKukreja @BenjaminPradere @GustavoVillold4 @TomFlaigMD @DrByronLee @KKBree @gautiermarcq @LiangChengMD @h_alahmadie @djmcconkey @BogdanaSchmidt @bkonety

[UroToday.com @urotoday]

Complete vs partial TURBT for #MIBC treatment. @UroLiedberg, @UroMoschini, & @BenjaminPradere join @UroDocAsh in this discussion on the extent of transurethral resection of bladder tumor (TURBT) needed in muscle-invasive #BladderCancer. #WatchNow on UroToday > https://t.co/hyvu8S01Vv

[Marco Moschini @UroMoschini]

@UroDocAsh Agree. In my opinion the disadvantage is regarding reconstruction: for neobladder is not possible to adeguately prepare the urethra and I prefer to not offer neobladder in these patients (I suppose functional outcomes are consistenly worse) for bricker increased risks of stenosis

[Luca Afferi @Luca_Afferi]

A honor to present the latest updates on urinary #biomarkers in HG NMIBC follow-up at the @Uroweb #uroonco congress. Have you read the DaBlaCa-15 Trial paper published in @EUplatinum? Check that out

Thanks inviting me @foxal72 @UroMoschini and to my opponent @evanguelosx 🙏🏻

[Roberto Contieri @RobertoContieri]

A 🧵 on our recent study on surveillance for IR-NMIBC @EurUrolOncol https://t.co/trmFp9Yd0y
There is limited evidence on follow-up for IR-NMIBC.
We used data from >2000 primary Ta–T1 NMIBC to stratify IR-NMIBC by recurrence risk and propose a risk-adapted follow-up approach.

[UroToday.com @urotoday]

Complete vs partial TURBT for #MIBC treatment. @UroLiedberg, @UroMoschini, & @BenjaminPradere join @UroDocAsh in this discussion on the extent of transurethral resection of bladder tumor (TURBT) needed in muscle-invasive #BladderCancer. #WatchNow on UroToday > https://t.co/hyvu8S01Vv

[UroToday.com @urotoday]

Complete vs partial TURBT for muscle-invasive #BladderCancer treatment. @UroLiedberg, @UroMoschini & @BenjaminPradere join @UroDocAsh in a discussion on the extent of transurethral resection of bladder tumor needed in #MIBC. They debate the value of complete resection when considering bladder-sparing approaches, neoadjuvant therapy, and clinical trials. #WatchNow on UroToday > https://t.co/uTCAuHIFES